INBANK
In 2011 Arthritis Research UK will be unrolling its ambitious plans to develop a national platform of clinical data, linked to a central archive of stored biological samples, linked to NHS data, (both primary and secondary care).
This central resource (INBANK) will provide access for recruitment to studies of both early and late stage inflammatory arthritis, the opportunity to access samples for biomarker development and testing and the facility for linking to follow up morbidity data to assess both clinical benefit and adverse events following treatment.
Arthritis Research UK is committed to providing substantial resources to support INBANK activities.
INBANK is a centralised, disease-based resource linking clinician- and patient-reported data with biological samples and routinely collected patient outcome data from NHS and related sources from other devolved administrations.
Find out more
INBANK is not a replacement or umbrella for funding clinical trials or supporting large scale patient cohort studies.
Find out more
INBANK will be centred on disease-based hubs which will be managed by Arthritis Research UK’s Clinical Studies Groups (CSGs) who have been tasked with prioritising and delivering the clinical research agenda to the relevant UK community.
Find out more
INBANK aims to establish within a single national centre at UK the facility for processing of biological samples, aliquoting, storage, archiving and retrieval. To achieve this there are some areas of information gathering and process development that need to be undertaken.
Find out more
The central component of INBANK is the ability to coordinate in a single platform.
Find out more
We want to ensure that INBANK adheres to appropriate standards of ethics and governance based on accepted best quality practice and acceptable to the stakeholders.
Find out more
Arthritis Research UK Head Office will assume a number of functions to ensure the successful working of INBANK.
Find out more
INBANK is an Arthritis Research UK conceived initiative but relies on buy in from the clinical and academic communities who will be the customers for the resource.
Find out more